Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects
Author:
Affiliation:
1. Global Drug Discovery, Clinical SciencesClinical Pharmacology Cardiovascular/Hematology, Bayer HealthCare PharmaceuticalsWuppertalGermany
2. Department of Biometry, PharmacometryBayer HealthCare PharmaceuticalsWuppertalGermany
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.26
Reference17 articles.
1. Perioperative Management of Antithrombotic Therapy
2. Oral Anticoagulant Therapy
3. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
4. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
5. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Role of Anticoagulants and Platelet Aggregation Inhibitors in the Treatment of Pseudoaneurysms and Risk of Venous Thrombosis;Angiology;2022-12-05
2. The value and limitations of new oral anticoagulant plasma level assessments;European Heart Journal Supplements;2022-02-01
3. Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics;Frontiers in Cardiovascular Medicine;2022-01-17
4. Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase;Journal of Personalized Medicine;2021-03-30
5. Administration of Direct Oral Anticoagulant Immediately after Unfractionated Heparin Bolus for the Treatment of Intermediate–High-Risk Pulmonary Thromboembolism;Annals of Vascular Diseases;2020-12-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3